股本结构
单位：万股
| 公告日期 | 2019-03-27 | 2018-11-14 | 2018-08-09 | 2018-08-09 | 2018-05-25 | 2018-05-10 |
|---|---|---|---|---|---|---|
| 证券总股本 | 975.83 | 931.50 | 931.50 | 784.09 | 567.13 | 2835.64 |
| 普通股本 | 975.83 | 931.50 | 931.50 | 784.09 | 567.13 | 2835.64 |
| 优先股 | 0.80 | 0.80 | 未披露 | 0.80 | 未披露 | 0.80 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2018-12-31 | 2018-09-30 | 2018-08-02 | 2018-06-30 | 2018-05-25 | 2018-03-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2019-03-27 | 975.83 | 0.80 |
更多>>
From December 31, 2017 to December 31, 2018
Conversion of pre-funded units
May 2018 Registered Direct Offering, net of offering costs $676
July 2018 Registered Direct Offering, net of offering costs $494
December 2018 Private Placement, net of offering costs $37
Common warrants exercised
|
2018-12-31 |
| 2018-11-14 | 931.50 | 0.80 |
更多>>
From December 31, 2017 to September 30, 2018
Conversion of pre-funded warrants
May 2018 Registered Direct Offering, net of offering costs of $676
July 2018 Registered Direct Offering, net of offering costs of $494
Exercise of warrants
|
2018-09-30 |
| 2018-08-09 | 931.50 | 未披露 | 定期报告 | 2018-08-02 |
| 2018-08-09 | 784.09 | 0.80 |
更多>>
from December 31, 2017 to June 30, 2018
Conversion of pre-funded warrants
May 2018 Registered Direct Offering, net of offering costs of $627
Exercise of warrants
|
2018-06-30 |
| 2018-05-25 | 567.13 | 未披露 |
更多>>
Fibrocell Science, Inc. (NASDAQ:FCSC) announced that it will effect a one-for-five reverse stock split of its common stock at 5:00 pm ET today. Beginning with the opening of trading on May 25, 2018, the Company's common stock will trade on The Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 315721407.
|
2018-05-25 |
| 2018-05-10 | 2835.64 | 0.80 |
更多>>
from December 31, 2017 to March 31, 2018
Conversion of pre-funded warrants
|
2018-03-31 |
| 2018-03-19 | 2835.64 | 未披露 | 定期报告 | 2018-03-06 |
| 2018-03-19 | 2594.02 | 0.80 |
更多>>
from December 31, 2016 to December 31, 2017
Issuance of Series A convertible preferred stock with detachable warrants net of issuance costs of $377
Exercise of liability-classified warrants
Conversion of promissory notes
Issuance of common stock with detachable warrants net of issuance costs $1,175
|
2017-12-31 |
| 2017-11-13 | 1472.00 | 0.80 |
更多>>
From December 31, 2016 to September 30, 2017
Issuance of Series A convertible preferred stock with detachable warrants, net of issuance costs of $377
Exercise of liability-classified warrants
Conversion of promissory notes
|
2017-09-30 |
| 2017-08-09 | 1471.72 | 未披露 | 定期报告 | 2017-08-03 |
| 2017-08-09 | 1471.00 | 0.80 |
更多>>
From December 31, 2016 to June 30, 2017
Issuance of Series A convertible preferred stock with detachable warrants, net of issuance costs of $377
Exercise of liability-classified warrants
Conversion of promissory notes
|
2017-06-30 |
| 2017-05-10 | 1469.51 | 0.80 |
更多>>
from December 31, 2016 to March 31, 2017
Issuance of Series A convertible preferred stock with detachable warrants, net of issuance costs of $377
Exercise of liability-classified warrants
|
2017-03-31 |
| 2017-03-10 | 1470.00 | 未披露 |
更多>>
On March 8, 2017, the Board approved a one-for-three reverse stock split of the Common Stock.The split effective as of 5:00 p.m. Eastern Time on March 10, 2017
|
2017-03-13 |
| 2017-01-27 | 4407.94 | 未披露 | 定期报告 | 2017-01-27 |
| 2017-03-09 | 4405.86 | 未披露 |
更多>>
from December 31, 2015 to December 31, 2016
Issuance of shares under “At-The-Market” equity program, net of offering costs
|
2016-12-31 |
| 2016-11-03 | 4397.83 | 未披露 | 定期报告 | 2016-11-01 |
| 2015-11-05 | 4389.88 | 未披露 |
更多>>
from December 31, 2014 to September 30, 2015
Proceeds from common stock offering, net
Exercise of stock options
Exercise of warrants
|
2015-09-30 |
| 2015-08-07 | 4388.72 | 未披露 | 定期报告 | 2015-07-31 |
| 2015-08-07 | 4091.31 | 未披露 |
更多>>
from December 31, 2014 to June 30, 2015
Exercise of stock options
|
2015-06-30 |
| 2015-05-08 | 4088.81 | 未披露 |
更多>>
from December 31, 2014 to March 31, 2015
Exercise of stock options
|
2015-03-31 |
| 2014-05-19 | 4085.68 | 未披露 |
更多>>
from December 31, 2013 to March 31, 2014
Issuance of common stock
|
2014-03-31 |
| 2014-03-17 | 4083.76 | 未披露 | 定期报告 | 2014-03-07 |
| 2014-03-17 | 3983.22 | 未披露 |
更多>>
From December 31,2012 to December 31,2013
Proceeds from equity financing, net
Issuance of common stock
Exercise of warrants
On April 29, 2013, the Company announced a reverse stock split on the basis of one share of common stock for each currently outstanding 25 shares of pre-split common stock that became effective on April 30, 2013.
|
2013-12-31 |
| 2013-11-14 | 3983.22 | 未披露 |
更多>>
On October 1, 2013, the Company completed an underwritten public offering of 11,000,000 shares of common stock at a public offering price of $4.10 per share.
|
2013-11-11 |
| 2013-11-14 | 2752.05 | 未披露 |
更多>>
from January 1, 2013 to September 30, 2013
Warrants exercised
Issuance of common stock for exclusive collaboration channel agreement
On April 29, 2013, the Company announced a reverse stock split on the basis of one share of common stock for each currently outstanding 25 shares of pre-split common stock that became effective on April 30, 2013.
|
2013-09-30 |
| 2013-08-13 | 2752.05 | 未披露 | 定期报告 | 2013-08-09 |
| 2013-08-13 | 2623.60 | 未披露 |
更多>>
from January 1, 2013 to June 30, 2013
Warrants exercised
On April 29, 2013, the Company announced a reverse stock split on the basis of one share of common stock for each currently outstanding 25 shares of pre-split common stock that became effective on April 30, 2013.
|
2013-06-30 |
| 2013-05-15 | 2622.99 | 未披露 |
更多>>
On April 29, 2013, the Company announced a reverse stock split on the basis of one share of common stock for each currently outstanding 25 shares of pre-split common stock that became effective on April 30, 2013.
|
2013-05-01 |
| 2013-04-01 | 65574.76 | 未披露 |
更多>>
from December 31, 2011 to December 31, 2012
Proceeds from equity financing, net
Preferred stock Series D and Series E converted
Reclass and exercise of warrants to equity
Conversion of note payable
Issuance of common stock for exclusive collaboration channel agreement
Cancellation of certificate
|
2012-12-31 |
From December 31, 2017 to December 31, 2018
Conversion of pre-funded units
May 2018 Registered Direct Offering, net of offering costs $676
July 2018 Registered Direct Offering, net of offering costs $494
December 2018 Private Placement, net of offering costs $37
Common warrants exercised
From December 31, 2017 to September 30, 2018
Conversion of pre-funded warrants
May 2018 Registered Direct Offering, net of offering costs of $676
July 2018 Registered Direct Offering, net of offering costs of $494
Exercise of warrants
from December 31, 2017 to June 30, 2018
Conversion of pre-funded warrants
May 2018 Registered Direct Offering, net of offering costs of $627
Exercise of warrants
Fibrocell Science, Inc. (NASDAQ:FCSC) announced that it will effect a one-for-five reverse stock split of its common stock at 5:00 pm ET today. Beginning with the opening of trading on May 25, 2018, the Company's common stock will trade on The Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 315721407.
from December 31, 2017 to March 31, 2018
Conversion of pre-funded warrants
from December 31, 2016 to December 31, 2017
Issuance of Series A convertible preferred stock with detachable warrants net of issuance costs of $377
Exercise of liability-classified warrants
Conversion of promissory notes
Issuance of common stock with detachable warrants net of issuance costs $1,175
From December 31, 2016 to September 30, 2017
Issuance of Series A convertible preferred stock with detachable warrants, net of issuance costs of $377
Exercise of liability-classified warrants
Conversion of promissory notes
From December 31, 2016 to June 30, 2017
Issuance of Series A convertible preferred stock with detachable warrants, net of issuance costs of $377
Exercise of liability-classified warrants
Conversion of promissory notes
from December 31, 2016 to March 31, 2017
Issuance of Series A convertible preferred stock with detachable warrants, net of issuance costs of $377
Exercise of liability-classified warrants
On March 8, 2017, the Board approved a one-for-three reverse stock split of the Common Stock.The split effective as of 5:00 p.m. Eastern Time on March 10, 2017
from December 31, 2015 to December 31, 2016
Issuance of shares under “At-The-Market” equity program, net of offering costs
from December 31, 2014 to September 30, 2015
Proceeds from common stock offering, net
Exercise of stock options
Exercise of warrants
from December 31, 2014 to June 30, 2015
Exercise of stock options
from December 31, 2014 to March 31, 2015
Exercise of stock options
from December 31, 2013 to March 31, 2014
Issuance of common stock
From December 31,2012 to December 31,2013
Proceeds from equity financing, net
Issuance of common stock
Exercise of warrants
On April 29, 2013, the Company announced a reverse stock split on the basis of one share of common stock for each currently outstanding 25 shares of pre-split common stock that became effective on April 30, 2013.
On October 1, 2013, the Company completed an underwritten public offering of 11,000,000 shares of common stock at a public offering price of $4.10 per share.
from January 1, 2013 to September 30, 2013
Warrants exercised
Issuance of common stock for exclusive collaboration channel agreement
On April 29, 2013, the Company announced a reverse stock split on the basis of one share of common stock for each currently outstanding 25 shares of pre-split common stock that became effective on April 30, 2013.
from January 1, 2013 to June 30, 2013
Warrants exercised
On April 29, 2013, the Company announced a reverse stock split on the basis of one share of common stock for each currently outstanding 25 shares of pre-split common stock that became effective on April 30, 2013.
On April 29, 2013, the Company announced a reverse stock split on the basis of one share of common stock for each currently outstanding 25 shares of pre-split common stock that became effective on April 30, 2013.
from December 31, 2011 to December 31, 2012
Proceeds from equity financing, net
Preferred stock Series D and Series E converted
Reclass and exercise of warrants to equity
Conversion of note payable
Issuance of common stock for exclusive collaboration channel agreement
Cancellation of certificate